{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:35:32Z","timestamp":1771655732093,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Interventions"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Despite the advent of drug-eluting stents, restenosis after endovascular intervention is still a major limitation in the treatment of cardiovascular disease. To regulate the multiple biological mechanisms underlying restenosis, we focused on inhibition of an important transcription factor, nuclear factor-kappaB (NF\u03baB), using a decoy strategy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>For site-specific application of NF\u03baB decoy oligodeoxynucleotides into target vessels during angioplasty, we developed a balloon catheter\u2013based delivery system combined with biocompatible nanoparticles as oligodeoxynucleotides carriers. To clarify the therapeutic effect at the site of neointima, balloon angioplasty of the rabbit carotid arteries was performed at 4 weeks after initial endothelial denudation. This delivery system exhibited successful transfer of fluorescence-labeled nanospheres into the neointima in short-term contact with target vessels, and fluorescence could be detected \u22651 week after angioplasty. Consistently, local application of NF\u03baB decoy oligodeoxynucleotides -loaded nanospheres resulted in significant inhibition of neointimal formation, associated with inhibition of NF\u03baB binding activity in the injured arteries. The therapeutic effects were caused by inhibition of macrophage recruitment through the suppression of monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, and CC chemokine ligand 4 expression and inhibition of vascular smooth muscle cell growth via a decrease in the expression of cyclin A and proliferating cell nuclear antigen. Importantly, application of NF\u03baB nanospheres accelerated restoration of the endothelial cell monolayer, associated with enhanced expression of phosphorylated Bcl-2 in endothelial cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>A drug-coated balloon catheter using NF\u03baB decoy oligodeoxynucleotides significantly inhibited the development of neointimal hyperplasia in rabbits. The present study indicates the possibility of a novel therapeutic option to prevent restenosis after angioplasty.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circinterventions.114.001522","type":"journal-article","created":{"date-parts":[[2014,11,19]],"date-time":"2014-11-19T03:28:35Z","timestamp":1416367715000},"page":"787-796","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor-\u03baB Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model"],"prefix":"10.1161","volume":"7","author":[{"given":"Takashi","family":"Miyake","sequence":"first","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Ihara","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Miyake","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tsukada","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Watanabe","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Kiguchi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Osaka, Japan (T.M., T.M., R.M.); Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, Osaka, Japan (T.M., H.N.); AnGes MG, Inc, Osaka, Japan (S.I., H.W.); Pharmaceutical and Beauty Science Research Center, Hosokawa Micron Corporation, Osaka, Japan (Y.T., H.T.); and Togo Medikit Co, Ltd, Miyazaki, Japan (H.M., H.K.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.108.781377"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1583\/05-1704.1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000116202.41966.d4"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.07.161"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800810904"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.3.723"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000160340.72641.87"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6101(00)00018-6"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.86.9.974"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118598"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.25.15817"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0897-894"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.82.10.1023"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2006.04.006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvn139"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.11.002"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.09.034"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.10.2995"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(00)00361-8"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0088com"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.746008"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65284-4"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00390.2009"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0875"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061254"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706356"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.106.675934"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090152"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/nn1018818"}],"container-title":["Circulation: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCINTERVENTIONS.114.001522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:39:46Z","timestamp":1715567986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.114.001522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1161\/CIRCINTERVENTIONS.114.001522"],"URL":"https:\/\/doi.org\/10.1161\/circinterventions.114.001522","relation":{},"ISSN":["1941-7640","1941-7632"],"issn-type":[{"value":"1941-7640","type":"print"},{"value":"1941-7632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-04-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}